Physician Focus on Parkinson's
Issue 13 (Spring 2010) - Quarterly CME Newsletter on Parkinson's Disease
To receive CME credit for this activity, please complete the post-test and evaluation below. Once submitted, a certificate will be issued within two weeks to the email address provided.
Click here to view Issue 13 online.
If you have any questions, please contact intellyst® Medical Education at 720-748-8800.
Target Audience
Neurologists, NPs and PAs specializing in neurology.
Statement of Need
Parkinson’s disease (PD) is the second most common neurodegenerative disease. The mean age of onset is 61 years, but may begin as early as age 40 or less. It affects an estimated half million to one million Americans. That number is expected to double in the next 25 years as the population ages and as treatments for other diseases prolong the survival of aging adults. PD is classified as a movement disorder, because its most prominent symptoms are tremor, rigidity, slowed movements, and postural instability. However, PD also includes a wide range of non-motor symptoms, including depression, anxiety, sleep disorder, and autonomic symptoms, and these may be at least as debilitating as motor symptoms for many patients.
Learning Objectives
At the conclusion of this activity, participants should be able to:
• Discuss non-motor features of Parkinson’s disease and their impact on quality of life, including, anxiety, depression, cognitive changes, sensory symptoms, and sleep disorders
• Describe medications available for treatment of motor symptoms of Parkinson’s disease in early and fluctuating disease as well as their side effects
• Summarize the unique nature of the delayed-start clinical trial design and its value in testing potential disease modifying agents in Parkinson’s disease
Disclosures
Lauren Seeberger, MD (Case Study Contributor)
Gary VanderArk, MD (Independent Reviewer)
Richard Robinson (Medical Writer)
Accreditation Statement
intellyst® Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
intellyst® Medical Education designates this activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
|
|
|
|
| Risk factors for Parkinsons disease include all of the following EXCEPT: |
|
| Genes known to cause Parkinsons disease include: |
|
| A large number of PD cases are known to be caused by exposure to: |
|
| Which single statement provides the best evidence that alpha-synuclein (AS) may be toxic in PD? |
|
| According to the Braak hypothesis, the PD disease process begins in the: |
|
| Evidence that PD may be a prion-like disorder includes all of the following EXCEPT: |
|
| AL, a male age 58, presents with depression. Upon questioning, AL reports a history of poor sense of smell and constipation, and a family history of shaking in the hands. Cognition is normal. What treatment(s) should be considered at this time? |
|
| TM is a 72-year old female with an 8-year history of PD. Her husband and main caregiver report she has become forgetful and has difficulty following through with activities. TMs PD symptoms are well controlled with levodopa, except for tremor which is only partially responsive to treatment. What dementia therapy might be best for this patient? |
|
Please indicate your level of agreement with the following two statements, with "1" indicating reject completely, and "5" indicating accept completely:
|
| Most patients with Parkinsons disease likely develop disease pathology in keeping with the Braak hypothesis. | |
| All important symptoms of Parkinsons disease are related to dopaminergic dysfunction, and are likely to be responsive to dopaminergic drugs. | |
|
|
|
|
Please evaluate the activity objectives by selecting how well each has been met, with 5 indicating excellent and 1 indicating poor.
|
| Discuss non-motor features of Parkinsons disease and their impact on quality of life, including anxiety, depression, cognitive changes, sensory symptoms, and sleep disorders | |
| Describe medications available for treatment of motor symptoms of Parkinsons disease in early and fluctuating disease as well as their side effects | |
| Summarize the unique nature of the delayed-start clinical trial design and its value in testing potential disease-modifying agents in Parkinsons disease | |
Please evaluate the effectiveness of the case study by Dr. Lauren Seeberger, in both areas listed below, with 5 indicating excellent and 1 indicating poor.
|
| Usefulness of information presented. | |
| Objectivity/fair balance of content. | |
| Do you intend to make changes or apply this information to your practice as a result of this activity? |
|
Please explain your response to the above question:
|
Was there any commercial bias perceived in relation to this activity? If yes, please describe.
|
Is there anything you would like to communicate to the authors?
|
Suggest topics you would like to see in future activities.
|
| First Name | |
| Last Name | |
| Degree/Credentials | |
| Phone | |
| Fax | |
| Email | |
By typing your name below, this will act as your signature.
|
| Signature | |
| Date | 
|
|
|
|
|
|